Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
13 Novembre 2024 - 10:01PM
Abivax Announces Former Prometheus COO,
Mark Stenhouse, Appointed as Board Observer
& Advisor to Abivax
PARIS, France, November 13, 2024, 10:00
pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX)
(“Abivax” or the “Company”), a clinical-stage biotechnology company
focused on developing therapeutics that harness the body’s natural
regulatory mechanisms to stabilize the immune response in patients
with chronic inflammatory diseases, today announced the appointment
of Mark Stenhouse as Board Observer and Advisor to Abivax.
Mr. Stenhouse brings more than 30 years of
experience in the biopharma industry. Most recently, he served as
Chief Operating Officer of Prometheus Biosciences, a biotechnology
company focused on gastrointestinal diseases that was acquired by
Merck for $10.8 billion in 2023. Prior to Prometheus, Mr. Stenhouse
spent over 25 years at AbbVie, most recently serving as Vice
President of U.S. Immunology. In this capacity, Mr. Stenhouse
oversaw U.S. sales and marketing teams for HUMIRA®.
In addition to his positions at Prometheus and
Abbvie, Mr. Stenhouse held an executive leadership role at Exact
Sciences. He holds a Bachelor of Science in Business Administration
from the College of Charleston.
Marc de Garidel, Chief Executive Officer
of Abivax, said: “We are pleased to welcome Mark
to the role of Board Observer and Advisor to Abivax. We expect his
perspective and extensive experience in gastroenterology and
immunology to undoubtedly support our continued progress as we head
toward commercialization of obefazimod and strengthen our
pipeline.”
Mark Stenhouse, Board Observer &
Advisor to Abivax, said: “I am impressed with the clinical
profile of obefazimod and its potential to address unmet needs in
the patient community. I look forward to working alongside the
Abivax management team and Board of Directors as the company
continues to advance toward key milestones.”
About ObefazimodObefazimod,
Abivax’s lead investigational drug candidate, is an orally
administered small molecule that was demonstrated to potentially
enhance the expression of a single microRNA, miR-124. Phase 2
clinical trials in patients with ulcerative colitis (UC) have
generated positive data, resulting in the initiation of a pivotal
global Phase 3 clinical trial program (ABTECT Program), with first
patients enrolled in the United States in October 2022. A Phase 2b
clinical trial in Crohn’s disease is ongoing, with the first
patient enrolled in October 2024, and exploration of potential
combination therapy opportunities in UC is ongoing.
About AbivaxAbivax is a
clinical-stage biotechnology company focused on developing
therapeutics that harness the body’s natural regulatory mechanisms
to stabilize the immune response in patients with chronic
inflammatory diseases. Based in France and the United States,
Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3
clinical trials for the treatment of moderately to severely active
ulcerative colitis. More information on the Company is available
at www.abivax.com. Follow us on LinkedIn and on X, formerly
Twitter, @Abivax.
Contact:Patrick MalloySVP,
Investor Relations, Abivaxpatrick.malloy@abivax.com+1 847 987
4878
DISCLAIMERThis press release
contains forward-looking statements, including those relating to
the Company’s business objectives. Words such as “continue,”
“expect,” “forward,” “potential” and variations of such words and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements include statements
concerning or implying the therapeutic potential of Abivax's drug
candidates and other statements that are not historical fact.
Although Abivax’s management believes that the expectations
reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and
statements are subject to various risks, contingencies and
uncertainties, many of which are difficult to predict and generally
beyond the control of Abivax, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. A description of these risks, contingencies and
uncertainties can be found in the documents filed by the Company
with the French Autorité des Marchés Financiers pursuant to its
legal obligations including its universal registration document
(Document d’Enregistrement Universel) and in our Annual Report on
Form 20-F filed with the U.S. Securities and Exchange Commission on
April 5, 2024 under the caption “Risk Factors.” These risks,
contingencies and uncertainties include, among other things, the
uncertainties inherent in research and development, future clinical
data and analysis, decisions by regulatory authorities, such as the
FDA or the EMA, regarding whether and when to approve any drug
candidate, as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates. Current results are not necessarily
indicative of future results. Special consideration should be given
to the potential hurdles of clinical and pharmaceutical development
including further assessment by the company and regulatory agencies
and IRBs/ethics committees following the assessment of preclinical,
pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data.
Furthermore, these forward-looking statements, forecasts and
estimates are only as of the date of this press release. Readers
are cautioned not to place undue reliance on these forward-looking
statements. Abivax disclaims any obligation to update these
forward-looking statements, forecasts or estimates to reflect any
subsequent changes that the Company becomes aware of, except as
required by law. Information about pharmaceutical products
(including products currently in development) that is included in
this press release is not intended to constitute an advertisement.
This press release is for information purposes only, and the
information contained herein does not constitute either an offer to
sell, or the solicitation of an offer to purchase or subscribe
securities of the Company in any jurisdiction. Similarly, it does
not give and should not be treated as giving investment advice. It
has no connection with the investment objectives, financial
situation or specific needs of any recipient. It should not be
regarded by recipients as a substitute for exercise of their own
judgment. All opinions expressed herein are subject to change
without notice. The distribution of this document may be restricted
by law in certain jurisdictions. Persons into whose possession this
document comes are required to inform themselves about and to
observe any such restrictions.
“Abivax” and the Abivax logo and other
trademarks or service marks of Abivax SA in this press release are
the property of Abivax SA. All other trademarks, trade names and
service marks appearing in this press release are the property of
their respective owners. Solely for convenience, the trademarks and
trade names in this press release may be referred to without the ®
and ™ symbols, but such references should not be construed as any
indicator that their respective owners will not assert their rights
thereto.
Grafico Azioni Abivax (EU:ABVX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Abivax (EU:ABVX)
Storico
Da Nov 2023 a Nov 2024
